Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 6/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
XSPRAY Stock Overview
Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden.
Xspray Pharma Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr54.30 |
52 Week High | kr163.90 |
52 Week Low | kr52.00 |
Beta | 1.43 |
1 Month Change | -4.40% |
3 Month Change | -10.25% |
1 Year Change | -44.59% |
3 Year Change | -22.43% |
5 Year Change | n/a |
Change since IPO | 72.93% |
Recent News & Updates
We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Shareholder Returns
XSPRAY | SE Biotechs | SE Market | |
---|---|---|---|
7D | -3.0% | 3.8% | -0.06% |
1Y | -44.6% | -20.7% | -22.4% |
Return vs Industry: XSPRAY underperformed the Swedish Biotechs industry which returned -20.6% over the past year.
Return vs Market: XSPRAY underperformed the Swedish Market which returned -22.4% over the past year.
Price Volatility
XSPRAY volatility | |
---|---|
XSPRAY Average Weekly Movement | 6.4% |
Biotechs Industry Average Movement | 8.2% |
Market Average Movement | 7.4% |
10% most volatile stocks in SE Market | 12.3% |
10% least volatile stocks in SE Market | 4.7% |
Stable Share Price: XSPRAY is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: XSPRAY's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 24 | Per Andersson | https://www.xspraypharma.com |
Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo for the treatment of chronic myeloid leukemia; HyNap-Sora for the treatment of renal cancer and liver cancer, as well as several forms of thyroid cancer; and HyNap-Dasa for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017.
Xspray Pharma Fundamentals Summary
XSPRAY fundamental statistics | |
---|---|
Market Cap | kr1.12b |
Earnings (TTM) | -kr101.72m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-11.0x
P/E RatioIs XSPRAY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
XSPRAY income statement (TTM) | |
---|---|
Revenue | kr0 |
Cost of Revenue | kr0 |
Gross Profit | kr0 |
Other Expenses | kr101.72m |
Earnings | -kr101.72m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 05, 2022
Earnings per share (EPS) | -4.92 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did XSPRAY perform over the long term?
See historical performance and comparisonValuation
Is XSPRAY undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for XSPRAY?
Other financial metrics that can be useful for relative valuation.
What is XSPRAY's n/a Ratio? | |
---|---|
n/a Ratio | 0x |
n/a | n/a |
Market Cap | kr1.12b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | n/a |
Enterprise Value/EBITDA | -9.9x |
PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does XSPRAY's PB Ratio compare to its peers?
XSPRAY PB Ratio vs Peers |
---|
Company | PB | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 8.1x | ||
ONCO Oncopeptides | 13.3x | 25.7% | kr1.6b |
ISOFOL Isofol Medical | 4.8x | 103.6% | kr1.3b |
HNSA Hansa Biopharma | 3.5x | -3.2% | kr2.2b |
HAMLET B Hamlet Pharma | 10.7x | n/a | kr432.3m |
XSPRAY Xspray Pharma | 2x | 98.5% | kr1.1b |
Price-To-Book vs Peers: XSPRAY is good value based on its Price-To-Book Ratio (2x) compared to the peer average (8.1x).
Price to Earnings Ratio vs Industry
How does XSPRAY's PE Ratio compare vs other companies in the SE Biotechs Industry?
Price-To-Book vs Industry: XSPRAY is good value based on its Price-To-Book Ratio (2x) compared to the Swedish Biotechs industry average (2.2x)
Price to Book Ratio vs Fair Ratio
What is XSPRAY's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PB Ratio | 2x |
Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate XSPRAY's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of XSPRAY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: XSPRAY (SEK54.3) is trading above our estimate of fair value (SEK8.89)
Significantly Below Fair Value: XSPRAY is trading above our estimate of fair value.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate XSPRAY's PEG Ratio to determine if it is good value.
Discover undervalued companies
Future Growth
How is Xspray Pharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score
6/6Future Growth Score 6/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
98.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: XSPRAY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.3%).
Earnings vs Market: XSPRAY is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: XSPRAY is expected to become profitable in the next 3 years.
Revenue vs Market: XSPRAY's revenue (133.6% per year) is forecast to grow faster than the Swedish market (5.5% per year).
High Growth Revenue: XSPRAY's revenue (133.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: XSPRAY's Return on Equity is forecast to be very high in 3 years time (42.5%).
Discover growth companies
Past Performance
How has Xspray Pharma performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-44.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: XSPRAY is currently unprofitable.
Growing Profit Margin: XSPRAY is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: XSPRAY is unprofitable, and losses have increased over the past 5 years at a rate of 44.4% per year.
Accelerating Growth: Unable to compare XSPRAY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: XSPRAY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.4%).
Return on Equity
High ROE: XSPRAY has a negative Return on Equity (-17.76%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is Xspray Pharma's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: XSPRAY's short term assets (SEK205.9M) exceed its short term liabilities (SEK18.7M).
Long Term Liabilities: XSPRAY's short term assets (SEK205.9M) exceed its long term liabilities (SEK878.0K).
Debt to Equity History and Analysis
Debt Level: XSPRAY is debt free.
Reducing Debt: XSPRAY has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: XSPRAY has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: XSPRAY has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 32.8% each year.
Discover healthy companies
Dividend
What is Xspray Pharma current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
0.61%
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate XSPRAY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate XSPRAY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if XSPRAY's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if XSPRAY's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as XSPRAY has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
3.8yrs
Average management tenure
CEO
Per Andersson (54 yo)
16.42yrs
Tenure
kr2,929,000
Compensation
Dr. Per Andersson Ph.D. has been the Chief Executive Officer of Xspray Pharma AB (publ) since 2006. Dr. Andersson serves as the Chief Executive Officer of Xspray Microparticles AB. Dr. Andersson joined XSp...
CEO Compensation Analysis
Compensation vs Market: Per's total compensation ($USD286.80K) is about average for companies of similar size in the Swedish market ($USD229.84K).
Compensation vs Earnings: Per's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: XSPRAY's management team is considered experienced (3.8 years average tenure).
Board Members
Experienced Board: XSPRAY's board of directors are considered experienced (3.1 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.5%.
Top Shareholders
Company Information
Xspray Pharma AB (publ)'s employee growth, exchange listings and data sources
Key Information
- Name: Xspray Pharma AB (publ)
- Ticker: XSPRAY
- Exchange: OM
- Founded: 2003
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: kr1.123b
- Shares outstanding: 20.68m
- Website: https://www.xspraypharma.com
Number of Employees
Location
- Xspray Pharma AB (publ)
- Råsundavägen 12
- Solna
- Stockholm County
- 169 67
- Sweden
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/06/29 00:00 |
End of Day Share Price | 2022/06/29 00:00 |
Earnings | 2022/03/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.